ATYR - aTyr Pharma, Inc.
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in May and June 2026. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Location: New York, NYFormat: 1x1 Investor Meetings Conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 3:45pm ETLocation: New York, NYFormat: Fireside ChatSpeaker: Sanjay S.
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma NASDAQ: ATYR said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting.
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.
aTyr Pharma (NASDAQ: ATYR) CEO Sanjay Shukla outlined the company's strategy to develop new therapies for inflammation and fibrosis based on tRNA synthetase biology during a presentation at the Leerink Partners Global Healthcare Conference. Shukla focused primarily on efzofitimod, the company's lead program, including results from a global Phase 3 study in pulmonary sarcoidosis and the
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.
aTyr Pharma, Inc. (NASDAQ: ATYR - Get Free Report) shares were down 2.1% during mid-day trading on Tuesday. The stock traded as low as $0.96 and last traded at $0.9888. Approximately 1,333,916 shares traded hands during trading, a decline of 52% from the average daily volume of 2,784,171 shares. The stock had previously closed at
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr's common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on February 17, 2026, the effective date of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's meeting request to discuss its lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis.
AUSTIN, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the pricing of its initial public offering of 10,526,315 shares of its Class A common stock, with 5,127,696 shares of Class A common stock being offered by Ethos and 5,398,619 shares of Class A common stock being offered by certain of Ethos' existing stockholders named in the prospectus, at an initial public offering price of $19.00 per share. Ethos will not receive any of the proceeds from the sale of the shares by the selling stockholders.
aTyr Pharma, Inc. (NASDAQ: ATYR - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 25,013,857 shares, a drop of 17.7% from the December 15th total of 30,385,566 shares. Based on an average daily volume of 2,246,751 shares,